InMed to Present INM-901 Data at Alzheimer's Association International Conference  2025

InMed to Present INM-901 Data at Alzheimer's Association International Conference 2025

Long-term INM-901 treatment in preclinical studies in advanced disease continues to show multi-modal activity

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it is presenting new preclinical data from its INM-901 program at the upcoming Alzheimer's Association International Conference (AAIC) 2025, the world's leading forum for Alzheimer's disease ("AD") and dementia research.

Data will be presented in a scientific poster entitled, "Therapeutic Potential of INM-901 in Mitigating Alzheimer's Disease Pathology: Insights from a Long-term 5xFAD Mouse Model Study". The Alzheimer's disease preclinical study measured hippocampal RNA expression, inflammatory markers, immunohistochemistry and behavioral differences following long-term treatment with INM-901 and as compared to healthy and to untreated diseased subjects in a well-established model.

This latest study evaluates INM-901 in the well-established 5xFAD AD mouse model, using a longer treatment duration and subjects with more advanced disease to validate and expand upon previous findings, which have demonstrated improvements in cognitive function, anxiety-related behavior, and sensory responsiveness.

Summary of INM-901 Long-term 5xFAD study:

  • Hippocampal RNA Expression - Several genes associated with inflammation, the endocannabinoid system, synaptic dysfunction and oxidative stress and apoptosis (cell death) were evaluated following treatment. In some cases, INM-901 demonstrated a dose-dependent trend towards a return to non-diseased baseline following treatment.

  • Inflammation - Treatment with INM-901 resulted in a significant reduction in the inflammatory biomarkers IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2 and NfL, suggesting a dose-dependent therapeutic effect in neuroinflammation.

  • Immunohistochemistry - Amyloid-beta (Aβ) immunoreactivity is reduced following INM-901 treatment in a dose-dependent manner. MAP2, the microtubule-associated protein 2 is a protein found in the neurons, especially in the dendrites and is involved in neurite outgrowth and signal transduction of the neurons, is partially restored with INM-901 treatment.

  • Behavioral - Cognitive function, anxiety-related behavior, and sensory responsiveness were restored or approaching normal following INM-901 treatment.

Conference Details
Conference: Alzheimer's Association International Conference (AAIC)
Dates: July 27-31, 2025
Location: Toronto, Canada
Website: https://aaic.alz.org/
Presentation poster will be available on InMed's website following the conference.

Dr. Eric Hsu, SVP, Preclinical Research & Development at InMed, commented, "The latest data continues to build on mounting preclinical evidence of the potential of INM-901 as a multi-targeted treatment candidate for Alzheimer's disease. INM-901 demonstrates a differentiated therapeutic approach in mitigating Alzheimer's pathology and we are excited to share the results from this study with the Alzheimer's disease community at the AAIC."

INM-901: Targeting multiple biological pathways in Alzheimer's disease

INM-901 is a proprietary small molecule drug candidate under development for the treatment of AD, with multiple mechanisms of action targeting key pathological features of the disease. Key attributes include:

  • Behavioral Improvements: INM-901 demonstrates positive trends in cognitive function, anxiety-related behavior, and sensory responsiveness.

  • Anti-Inflammatory Action: INM-901 demonstrates strong neuroinflammatory modulation in AD pathology.

  • Neuroprotection: INM-901 significantly reduces amyloid-beta-induced cell death.

  • Neuronal Regeneration: INM-901 promotes neurite outgrowth, indicating its ability to enhance neuronal connectivity and function.

  • Molecular Validation: mRNA data aligns with behavioral findings, supporting observed improvements in cognition, memory and neurogenesis.

About AAIC

The Alzheimer's Association International Conference ('AAIC') is a premier global event dedicated to advancing research and innovation in the fields of dementia and cognitive health. This annual gathering unites scientists, medical professionals, and thought leaders from across the globe to share the most recent discoveries, developments, and best practices in the field. Topics range from groundbreaking research to new care techniques, all focused on improving early diagnosis, managing risks, and enhancing approaches to Alzheimer's and related diseases.

About InMed:

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.

Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.com

Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: the potential efficacy of INM-901, INM-901's ability to treat Alzheimer's, marketability and uses for INM-901.

Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-Q, in Item 1A. of the Quarterly Report for the period ended March 31, 2025, and other filings with the Securities and Exchange Commission on www.sec.gov.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/260250

News Provided by Newsfile via QuoteMedia

INM
The Conversation (0)
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

  • Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathology

  • Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

  • Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that Eric A. Adams, InMed's CEO, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 18th, 2025.

DATE : September 18 th
TIME: 2:00 PM ET
LINK: REGISTER HERE
Available for 1x1 meetings: September 18-23. Please schedule 1x1 meetings here.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Life Science Virtual Investor Forum Agenda Announced for September 18th

Life Science Virtual Investor Forum Agenda Announced for September 18th

Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Science Virtual Investor Forum to be held September 18th. This event is co-hosted by Zacks SCR.

Individual investors, institutional investors, advisors, and analysts are invited to attend.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that the Company will be participating in the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025, in New York. During the conference, members of InMed's management team will also be conducting one-on-one meetings with investors. Additionally a corporate presentation from the Company will be available online.

In the presentation, Mr. Michael Woudenberg, InMed's Chief Operating Officer, will highlight updates and progress of InMed's pipeline including recent data from the Company's leading pharmaceutical program INM-901 in the treatment of Alzheimer's, that was recently presented at Alzheimer's Association International Conference (AAIC) 2025, the world's leading forum for Alzheimer's disease and dementia research.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of $2.561 per share (or pre-funded warrant in lieu thereof) and associated short-term preferred investment option. The short-term preferred investment option issued in the offering is exercisable immediately upon issuance at an exercise price of $2.436 per share and will expire eighteen months from the effective date of the Resale Registration Statement (as defined below).

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News